Tanvex BioPharma, Inc. (TPE:6541)

Tanvex BioPharma Ratios and Metrics

Market cap in millions TWD. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 9, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	12,091	10,697	8,715	12,377	20,476	9,894
Market Cap Growth	67.21%	22.75%	-29.59%	-39.55%	106.96%	-9.41%
Enterprise Value	13,056	11,603	9,691	13,133	19,692	9,494
Last Close Price	50.70	64.66	63.95	101.30	167.69	106.94
PS Ratio	108.94	308.48	141.91	552.43	3787.62	32979.06
PB Ratio	2.48	11.98	10.61	8.90	7.33	3.78
P/TBV Ratio	7.42	12.07	10.66	8.97	7.35	3.79
EV/Sales Ratio	117.63	334.59	157.80	586.21	3642.61	31645.92
Debt / Equity Ratio	0.32	1.85	2.11	1.32	0.63	0.58
Asset Turnover	0.02	0.01	0.02	0.01	0.00	0
Inventory Turnover	0.67	0.16	0.01	0.32	0.03	0.00
Quick Ratio	1.41	1.17	1.15	2.68	9.06	5.93
Current Ratio	2.17	1.94	1.66	3.44	9.66	6.41
Return on Equity (ROE)	-44.17%	-161.17%	-193.18%	-78.41%	-56.99%	-74.47%
Return on Assets (ROA)	-15.80%	-30.84%	-42.47%	-24.68%	-22.00%	-33.03%
Return on Capital (ROIC)	-16.88%	-33.29%	-45.40%	-25.78%	-22.99%	-34.93%
Earnings Yield	-11.60%	-12.91%	-24.52%	-13.26%	-7.54%	-21.27%
FCF Yield	-10.36%	-11.75%	-17.29%	-11.53%	-6.92%	-18.74%
Buyback Yield / Dilution	-40.86%	-20.44%	-9.60%	-8.31%	-21.32%	-9.25%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.